Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Case Reports
Share your love
Ocugen Shares Positive OCU410 Trial Results for GA
Ocugen has released encouraging preliminary findings from the Phase 1 portion of its Phase 1/2 OCU410 ArMaDa clinical trial, focused on treating geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The results demonstrate the potential of OCU410 as…
Cequa Shows Positive Phase 4 Results for Dry Eye
Sun Pharmaceutical has shared new Phase 4 clinical trial data, showcasing the efficacy of Cequa (cyclosporine ophthalmic solution) 0.09% in treating dry eye disease (DED). The results reveal that Cequa provides sustained improvements in patients whose symptoms were inadequately managed…
MediPrint Announces Positive Results for Glaucoma Lens
MediPrint Ophthalmics has revealed positive findings from its Phase 2b clinical trial for LL-BMT1, a 3D-printed, drug-eluting contact lens designed to treat mild to moderate glaucoma. These results, presented by Ian Ben Gaddie, OD, FAAO, at the American Academy of…
Okyo Pharma’s Phase 2 Trial for Neuropathic Corneal Pain
Okyo Pharma announced its plan to initiate a phase 2 clinical trial for OK-101 in the treatment of neuropathic corneal pain (NCP), scheduled to begin in the third quarter of 2024. This one-year study follows promising results from preclinical animal…
NexThera Submits IND Application for NT-101 for Wet AMD
NexThera has officially submitted a Phase 1/2a Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NT-101, an innovative non-invasive eye drop treatment targeting wet age-related macular degeneration (wet AMD). Proprietary Delivery Platform: Advancing Treatment…
Funding Boost for PulseMedica’s Eye Floater Technology
PulseMedica has successfully raised a total of $12 million in their recent pre-Series A financing round, marking a significant milestone in their pursuit of innovative eye floater diagnostic and treatment technologies. Accelerating Clinical Validation and Expansion Efforts This funding round…
FDA Clears Enhanced SPECTRALIS® OCTA Module by Heidelberg
Heidelberg Engineering announced the FDA clearance of its upgraded SPECTRALIS® OCTA Module featuring SHIFT technology. This advancement promises to significantly reduce acquisition time by 50%, marking a pivotal development in clinical efficiency and diagnostic precision within ophthalmology. Enhancing Clinical Utility…
Outlook Therapeutics Receives UK Approval of Lytenava for AMD
Outlook Therapeutics announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (AMD) in the UK. Lytenava is the first and only authorized…
Beacon Therapeutics Propels Gene Therapy with $170M Funding
Beacon Therapeutics has successfully raised $170 million in Series B funding, marking a significant step forward in advancing its portfolio of ophthalmic gene therapies. The funds are earmarked to support the ongoing clinical development of Beacon’s lead candidate, AGTC-501, designed…
Novel AI Boosts Geographic Atrophy Clinical Trial Efficiency
A new artificial intelligence (AI) system developed by researchers from UCL and Moorfields Eye Hospital could potentially revolutionize the recruitment process for clinical trials aimed at treating Geographic Atrophy (GA), an advanced form of dry age-related macular degeneration (AMD) that…